Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
The pharmacoeconomics of Alzheimer's disease
H. M. Fillit
Brookdale Department of Geriatrics and Palliative Medicine
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Article
›
peer-review
61
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The pharmacoeconomics of Alzheimer's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Comorbidity
25%
Managed Care Organization
25%
Diabetes
12%
Early Treatment
12%
Heart Failure
12%
Health Care Costs
12%
Reimbursement
12%
Medical Management
12%
Cause of Disability
12%
Emergency Department Visits
12%
Donepezil
12%
Cost-effectiveness
12%
Outpatient Care
12%
Inpatient Stay
12%
Acetylcholinesterase Inhibitors (AChEI)
12%
Direct Medical Costs
12%
Medicaid Managed Care
12%
Disease Management Program
12%
Medical Claims
12%
Potential Savings
12%
Nursing Home Care
12%
Indirect Medical Costs
12%
Nursing and Health Professions
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Disease Management
33%
Patient with Alzheimer's Disease
33%
Managed Care Organization
33%
Comorbidity
33%
Medicare
16%
Emergency Ward
16%
Reimbursement
16%
Congestive Heart Failure
16%
Cost Effectiveness Analysis
16%
Donepezil
16%
Cholinesterase Inhibitor
16%
Outpatient Care
16%
Nursing Home Care
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Comorbidity
25%
Disease
12%
Congestive Heart Failure
12%
Cholinesterase Inhibitor
12%
Donepezil
12%